The Rhythm | Issue 9
Issue 9 | Week of 1 June 2026
No major general cardiology congress fell in this window, and the week's most-discussed evidence arrived mainly through journal publication, including two early-phase platform studies in the New England Journal of Medicine.
Cardiology Intelligence Briefing: the distance between promise and proof
This week showed cardiology at its most ambitious and its most disciplined. At one end were two first-in-class platforms that point toward a very different future: one-dose genetic prevention and biological repair of failing myocardium. A single infusion of an in vivo base editor switched off PCSK9 (proprotein convertase subtilisin-kexin type 9) and lowered low-density lipoprotein cholesterol (LDL-C) by up to 62%, with reductions sustained for up to 18 months.2 Engineered heart muscle grown from stem cells and implanted onto failing ventricles was associated with thicker target heart walls and a small rise in ejection fraction in advanced heart failure.1 Both findings are remarkable. Neither is yet practice-changing. They come from small, uncontrolled, early-phase studies built on biochemical or structural signals rather than clinical outcomes.
The rest of the week was less futuristic, but closer to the work of everyday cardiology. A nurse-managed, alert-driven heart failure strategy missed its primary endpoint, exposing a familiar weakness in digital medicine: identifying risk does not help unless the system can act on it quickly and consistently.3 A 15-trial synthesis of nearly 49,000 patients after percutaneous coronary intervention (PCI) strengthened the case for prasugrel where it is safe to use, while preserving the need for individual bleeding-risk judgement.4 And a 716-trial network meta-analysis of blood pressure (BP) therapies challenged the assumption that adding drugs necessarily worsens tolerability, with angiotensin II receptor blocker (ARB)-containing combinations emerging as some of the best-tolerated options.5
This was not a week that changed cardiology's direction. It was a week that clarified the distance between possibility and proof. The frontier papers show what may be possible; the synthesis papers refine decisions clinicians already make rather than replacing them. Taken together, they capture the field's current tension: the future is moving toward one-dose therapies, engineered tissue, and continuous monitoring, while the strongest evidence still asks the older, harder question of whether these advances actually improve outcomes for patients.
